Neurogen Brain and Spine Institute
16
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
100.0%
16 terminated/withdrawn out of 16 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Stem Cell Therapy in Duchenne Muscular Dystrophy
Role: lead
Cell Therapy as Treatment for Cerebral Palsy
Role: lead
Stem Cell Therapy for Cerebral Palsy
Role: lead
Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis
Role: lead
Stem Cell Therapy in Limb Girdle Muscular Dystrophy
Role: lead
Safety and Efficacy of Stem Cell Therapy in Spinal Cord Injury
Role: lead
Stem Cell Therapy in Autism Spectrum Disorders
Role: lead
Cell Therapy in Limb Girdle Muscular Dystrophy
Role: lead
Autologous Stem Cell Therapy in Stroke
Role: lead
Safety and Efficacy of Autologous Stem Cell Therapy in Chronic Stroke
Role: lead
Stem Cell Therapy for Amyotrophic Lateral Sclerosis
Role: lead
Stem Cell Therapy in Muscular Dystrophy
Role: lead
Stem Cell Therapy in Spinal Cord Injury
Role: lead
Stem Cell Therapy in Mental Retardation
Role: lead
Stem Cell Therapy in Traumatic Brain Injury
Role: lead
Stem Cell Therapy in Incurable Neurological Disorders
Role: lead
All 16 trials loaded